Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer.

Emily Harrold Fergus Keane Henry S Walch Joanne F Chou Jenna Sinopoli Silvia Palladino Duaa H Al-Rawi Kalyani Chadalavada Francesco Pantano Sree Chalasani Jessica Yang Andrea Cercek Jinru Shia Marinela Capanu Samuel F Bakhoum Nikolaus Schultz Walid K Chatila Rona Yaeger

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Our genomic analysis suggests that high baseline CIN or effective induction of enhanced mutagenesis on targeted therapy underlies rapid progression. Longer response appears to result from a progressive acquisition of genomic or chromosomal instability in the underlying cancer or from the chance event of a new resistance alteration.

Keyphrases

copy number
papillary thyroid
multiple sclerosis
crispr cas
squamous cell
smoking cessation
replacement therapy
genome wide